Meridian Bioscience — Q1 FY2019 Earnings Presentation
12 slides from Meridian Bioscience's earnings presentation, Jan 24, 2019
Slide 1: F2019 First Quarter Financial Results
Exhibit 99.2 Meridian soscience- —wT F2019 First Quarter Financial Results January 24, 2019
Slide 2: Forward-looking statements safe harbor
The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this report contains forward-looking statements within the meaning of Section 27A of th
Slide 3: Non-GAAP financial measures notice
Certain financial measures presented in this presentation, such as operating expenses, operating income, net earnings and diluted earnings per share, excluding as applicable the effects of restructuring costs, litigation costs, and certain one-time effects of the U.S. tax reform act, are not recogni
Slide 4: Q1 Financial Results
Q1 Financial Results eww”
Slide 5: Adjusted (Non-GAAP) Highlights
Adjusted (Non-GAAP) Highlights: 2019 2018 Change • Consolidated revenue down 1.5% (1% constant currency); Revenue $51,480 $52,283 -1.5% Diagnostics down 2%; Life Science flat Gross Margin 61.3% 61.2% +0.1 pts • LS gross margin improvements offset Dx pricing and volume effects Operating expenses $20,
Slide 6: Diagnostics and Life Science segment results
Diagnostics (Adjusted Non-GAAP) Life Science (Adjusted Non-GAAP) 2019 2018 Change 2019 2018 Change Revenue $36,665 $37,490 -2.2% Revenue $14,815 $14,793 +0.1% Operating income $8,786 $8,569 +2.5% Operating income $5,129 $2,943 +74.3% % Margin 24.0% 22.9% +1.1 pts % Margin 34.6% 19.9% +14.7 pts Reven
Slide 7: F2019 guidance
Consolidated net Consolidated net 2%-4% growth Flat to 2% growth revenues revenues Operating margin ~20% (GAAP/Non-GAAP) Operating margin ~19% (GAAP), ~20% (Non-GAAP) Tax rate 25.5% Tax rate 24.5%-25.0% Earnings per Share $0.74-$0.76 (GAAP/Non-GAAP) Earnings per Share $0.72-$0.74 (GAAP), $0.74-$0.76
Slide 8: Business Outlook
Business Outlook eww”
Slide 9: F2019 Situation, New Products and Growth Drivers
F2019 Situation New Products Growth Drivers Opportunistic Strategic partnership partnerships in with DiaSorin to drive • Working to re-build core product ® ™ Calprotectin and automated HpSA pipeline – Execute Curian Lyme testing at larger • Multifaceted approach to bridge hospital labs to core repla
Slide 10: Life Science quarterly growth rates and new products
30% Highly variable 25% quarterly growth rates 20% 15% Tropical Diseases Fertility Markers New: Nipah Mayaro New: AMH Inhibin B 10% 5% 0% Q1-17 Q2-17 Q3-17 Q4-17 Q1-18 Q2-18 Q3-18 Q4-18 Q1-19 -5% High Performance & New Assay -10% Stable PCR Enzymes Interference Blockers ® New: Lyo ready TRU Block Ul
Slide 11: F2019 and Beyond
F2019 and Beyond • Early stages of strategy execution in Diagnostics amid increasing competitive pressures • Balancing near-term earnings with investment for future growth • Total R&D investment to increase over time and accelerate with more clinical trial activity • Commercial, product and cost ini
Slide 12: Questions & Answers
Questions & Answers eww”
Meridian Bioscience — Q1 FY2019 Earnings Presentation on 6ix